Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock

Crit Care Med. 2010 Oct;38(10):2016-23. doi: 10.1097/CCM.0b013e3181ef4694.

Abstract

Objective: To compare the effects of a first-line therapy of combined arginine vasopressin, levosimendan, and norepinephrine with arginine vasopressin + norepinephrine or norepinephrine alone in ovine septic shock.

Design: Prospective, randomized, controlled laboratory experiment.

Setting: University animal research facility.

Subjects: Twenty-one chronically instrumented sheep.

Interventions: After the onset of fecal peritonitis-induced septic shock (mean arterial pressure <60 mm Hg), sheep were randomly assigned to receive first-line treatment with arginine vasopressin (0.5 mU·kg·min), combined arginine vasopressin (0.5 mU·kg·min) and levosimendan (0.2 μg·kg·min), or normal saline (each n = 7) for 24 hrs. In all groups, open-label norepinephrine was additionally titrated to maintain mean arterial pressure at 70 ± 5 mm Hg, if necessary.

Measurements and main results: Arginine vasopressin + levosimendan + norepinephrine improved left ventricular contractility (higher stroke work indices at similar or lower preload) and pulmonary function (Pao2/Fio2 ratio) when compared with the other groups (p < .05 each). Both nonadrenergic treatment strategies reduced open-label norepinephrine doses. However, only arginine vasopressin + levosimendan + norepinephrine limited fluid requirements and positive fluid balance vs. both other groups (p < .05 each). In addition, arginine vasopressin + levosimendan + norepinephrine increased mixed venous oxygen saturation as compared with arginine vasopressin + norepinephrine. Histologic tissue analyses and pulmonary hemeoxygenase-1 activity revealed no differences among groups. Notably, arginine vasopressin + levosimendan + norepinephrine therapy reduced pulmonary 3-nitrotyrosine levels (p = .028 vs. control animals) as well as urinary protein/creatinine ratio (p < .05 each) and slightly prolonged survival when compared with both other groups (4 hrs vs. arginine vasopressin + norepinephrine: p = .013; 7 hrs vs. norepinephrine alone: p = .003).

Conclusions: First-line cardiovascular support with combined arginine vasopressin and levosimendan supplemented with norepinephrine improves myocardial, vascular, pulmonary, and renal function as compared with arginine vasopressin + norepinephrine in septic shock.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginine Vasopressin / pharmacology*
  • Blood Gas Analysis
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Drug Therapy, Combination
  • Hydrazones / pharmacology*
  • Lung / drug effects
  • Lung / physiopathology
  • Myocardial Contraction / drug effects
  • Myocardial Contraction / physiology
  • Norepinephrine / pharmacology
  • Pulmonary Wedge Pressure / drug effects
  • Pulmonary Wedge Pressure / physiology
  • Pyridazines / pharmacology*
  • Sheep
  • Shock, Septic / drug therapy*
  • Shock, Septic / physiopathology
  • Simendan
  • Vascular Resistance / drug effects
  • Vascular Resistance / physiology
  • Vasoconstrictor Agents / pharmacology*
  • Water-Electrolyte Balance / drug effects
  • Water-Electrolyte Balance / physiology

Substances

  • Hydrazones
  • Pyridazines
  • Vasoconstrictor Agents
  • Arginine Vasopressin
  • Simendan
  • Norepinephrine